Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Senti Biosciences (SNTI) Liabilities and Shareholders Equity (2021 - 2025)

Senti Biosciences has reported Liabilities and Shareholders Equity over the past 5 years, most recently at $51.2 million for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity fell 47.65% year-over-year to $51.2 million; the TTM value through Dec 2025 reached $255.2 million, down 25.95%, while the annual FY2025 figure was $51.2 million, 47.65% down from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $51.2 million at Senti Biosciences, down from $52.7 million in the prior quarter.
  • Over five years, Liabilities and Shareholders Equity peaked at $231.9 million in Q2 2021 and troughed at $373657.0 in Q1 2021.
  • A 5-year average of $126.0 million and a median of $110.8 million in 2023 define the central range for Liabilities and Shareholders Equity.
  • Biggest five-year swings in Liabilities and Shareholders Equity: skyrocketed 61698.89% in 2022 and later crashed 56.19% in 2024.
  • Year by year, Liabilities and Shareholders Equity stood at $96.7 million in 2021, then skyrocketed by 86.96% to $180.8 million in 2022, then tumbled by 33.91% to $119.5 million in 2023, then fell by 18.11% to $97.8 million in 2024, then tumbled by 47.65% to $51.2 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for SNTI at $51.2 million in Q4 2025, $52.7 million in Q3 2025, and $68.5 million in Q2 2025.